Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT06464861 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

CD19-CARNK/T
Start date: June 10, 2024
Phase: Phase 1
Study type: Interventional

To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma

NCT ID: NCT06464185 Recruiting - Clinical trials for B-cell Non-Hodgkin Lymphoma

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

Start date: April 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study was to analyze the safety and efficacy of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's (B-NHL) lymphoma. The main questions it aims to answer: 1. The safety of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells in B-NHL; 2. The effect of different doses of bispecific antibody maintenance therapy on CAR-T cell expansion.

NCT ID: NCT06461182 Recruiting - Clinical trials for Indolent B-Cell Non-Hodgkin Lymphoma

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

PentixaFor
Start date: April 29, 2024
Phase: Phase 2
Study type: Interventional

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

NCT ID: NCT06458439 Not yet recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

NCT ID: NCT06446128 Active, not recruiting - Clinical trials for Non-Hodgkin Lymphoma, B-cell

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Start date: April 1, 2024
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

NCT ID: NCT06445803 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.

NCT ID: NCT06445517 Recruiting - Clinical trials for Advanced Solid Tumors

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Start date: April 25, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma

NCT ID: NCT06441097 Not yet recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Start date: December 31, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

NCT ID: NCT06415708 Recruiting - B Cell Lymphoma Clinical Trials

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-center, single-arm clinical study to evaluate the efficacy and safety of maintenance therapy with obinutuzumab for 2 years in patients ≥ 18 years of age with newly diagnosed mature B-cell lymphoma (including follicular lymphoma[FL], marginal zone cell lymphoma[MZL] , waldenström macroglobulinemia[WM], hairy-cell leukemia variant[HCL-v]) who achieved ≥ PR after 6 cycles of obinutuzumab in combination with bendamustine.

NCT ID: NCT06414148 Not yet recruiting - Clinical trials for Relapsed/Refractory Large B-cell Lymphoma

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

EpLCART
Start date: May 7, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.